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We recently reported the use of a chronic dialytic 
delivery system for intrastriatal administration of 
quinolinic acid in the rat.” This system produces 
~~~e~ration with some characteristics simihtr to 
posf ntortem brain tissue from Hun~on’s disease 
patients, including reduced cytochrome oxidase stain- 
ing, a decreased number of Nissl-stained neurons, and 
relative sparing of striatal NADPH-diaphorase con- 
taining neurons.’ The present findings show that 
chronic dialytic delivery of q~~g~c acid also pro- 
duces a Huntington’s disease-like pattern of reduced 
caibindin and parvalbumin perikaryal hnmunoreactiv- 
ity that is reversed in rats allowed four to eight weeks’ 
recovery after cessation of quinolinic acid. Further- 
more, cytochrome oxidase staining and the number of 
Nissl-stained cells were unhand in the region of 
transient calbindin and parvalbumiu immunoreactive 
perikaryal staining alterations. These results suggest 
that changes in calbindin and parvalbumin perikaryal 
immunoreactivity provide a relatively sensitive measure 
of quinolitic acid induced ~urotoxici~. The revers- 
ible nature of reduced perikaryal immu~reactivity 
suggests a premorbid state of neurotoxicity, possibly 
marked by cellular redistribution of calbindin and 
parvalbumin. 
Quinolinic acid acts as an agonist at N-methyl-D- 
aspartate (NMDA) receptors, causing an increase 
in intracellular calcium concentration.20 To maintain 
intracellular ionic equilibrium, calcium can be se- 
questered by intracellular organelles or buffered by 
calcium binding proteins. I3 Excessive calcium influx 
through the NMDA receptor complex results in 
excitotoxicity. 10*‘5~2’*22 Cells containing the calcium 
fTo whom correspondence. should be addressed at the 
Department of Ne~ro~o~/Neuro~ience Laboratory 
Building. 
Abbreviations: HD, Huntington’s disease; NMDA, N- 
methyl-o-aspartate. 
buffering protein, calbindin, are reduced in post 
mortem striatal tissue from all grades of Huntington’s 
disease (HD).13,19 Cells containing parvalbumin, 
another calcium buffering protein, appear more re- 
sistant and are reduced only in tissue from advanced 
HDe9 
In a previous report, Nissl staining showed that 
chronic intrastriatal dialytic delivery of 4 mM quino- 
linic acid had no effect on neuronal density, while 
15 mM quinolini~ acid produced a decrease in neur- 
onal density that was restricted to an area approxi- 
mately 400 pm radial to the dialysis probe in the rat.4 
In the present experiments, quantitation of Nissl- 
stained neuron density revealed findings identical to 
the previous study for both 4 and 15 mM concen- 
trations of quinolinic acid. However, as shown 
in Fig. 1, perikaryal calbindin and parvalbumin 
immunoreactivity was significantly reduced through- 
out a region 400pm radial to the dialysis probe in 
animals receiving 4 mM quinolinic acid (calbindin: 
control 170 + 9.55 vs quinolinic acid 73.3 _t 11.19, 
P < 0.001; parvalbumin: control 24.25 -+ 2.33 vs 
quinolinic acid 14.3 + 2.68, P < 0.005; mean number 
of perikarya _+ S.E.M., two-tailed Student’s paired 
t-test). Animals that received 15 mM quinolinic 
acid showed reduced calbindin and parvalbumin 
perikaryal immunoreacti~ty throughout most of the 
striatum (Table 1, Fig. 2). 
There was a dose-dependent effect of quinolinic 
acid on cytochrome oxidase staining. Analysis of 
brain selections containing the dialysis probe tract 
revealed that 15 mM quinolinic acid produced a 
significantly greater area of decreased staining than 
did 4 mM quinolinic acid (Veh 12.8 f 2.53 mm2 vs 
4mM 27.1 f l.22mm2, meanfS.E.M., P ~0.001; 
4mM 27.1 -+ 1.22mm2 vs 15mM 56.1 j-5.91 mm2, 
P < 0.001; Student’s unpaired t-test). For both doses, 
the decrease in perikaryal calbindin and parvalbumin 
immunoreactivity was apparent well beyond the area 
of decreased cytochrome oxidase staining. 
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Fig. 1. Data from Experiment 1 showed that 21 days of 4 mM quinolinic acid produced a significant 
decrease in cdlbindin and parvalbumin immunoreactive perikarya compared to control striata. Detailed 
methods for the dialytic delivery system are described elsewhere.’ Perikarya were analysed in a 
I .02 x 10 - ’ mm’ volume of striatal tissue 400 pm radial from the necrotic core or a homologous region 
in the contralateral (control) striatum of t 2 SpragueDawley rats (Harlan Sprague-Dawiey, Inc. 
Indianapolis, IN). In the control striatum calbindin (A) and parvalbum~n (C) immunoreactive staining 
is normal. Exposure to 4 mM quinolinic acid for 21 days produced a significant decrease in calbindin (El) 
and parvalbumin (D) immunoreactive perikarya and an increase in neuropil staining. Calbindin and 
parvalbumin antibodies (Sigma) were diluted 1: 2000 and immunohistochemical assays performed using 
Vectastain mouse IgG Elite ARC kit (Vector Labs, Inc.) according to manufacturer’s instructions. There 
was no significant difference in the number of nissl-stained cells (not shown) in control (186.5 + 10.46) 
vs quinolinic acid-exposed (160.3 f 14.82) striata. Scale bar = IOOpm. 
Table 1, Combined data from Experiment 2 showing a relatively rapid and sustained loss, and 
Experiment 3 showing the subsequent recovery, of calbindin and parvalbumin immunoreactive 
perikaryal staining in response to 15 mM quinolinic acid 
Calbindin Parvalbumin 
Quinolinic acid Control Qu~noli~c acid Control 
Time course 
5 days (n = 6) 84.0 f 16.8** 246.0 + 15.4 9.2 + 2.4** 25.8 + 2.1 
10 days (n = 4) 48.0 k 24.4* 212.1 + 26.1 14.4 f. 5.5 25.0 + 2.5 
15 days (n = 4) 73.8 & 19.1* 251.0 +44.4 15.7 + 0.9* 29.3 + 2.4 
21 days (n = 7) 65.4 F 23.3** 246.6 & 24.6 II.5 * 2.0* 19.0 + 0.8 
Recovered 
4 weeks (n = 5) 162.4 f 20.1 209.6 k 30.5 15.8 + 1.2 16.2 + 1.8 
8 weeks (n = 4) 118.3 k 33.9 193.3 + 36.3 18.0 + 1.8 19.8 & 3.3 
Perikarya were analysed in a 1.02 x 10 _I mm3 volume of tissue from the ventral lateral 
striatum approximately 1 mm caudal from the necrotic core. Two-tailed paired Student’s 
t-tests were used to determine significant changes in the number of calbindin and 
parvaibu~n ~mmunor~c~ve perikarya between control and quinoIinic acid exposed striata 
(*P < 0.05 **P < 0.005). 
Cresyl Violet stained sections were also analysed in animals receiving 21 days in = 7) 
administration. There was no significant difference in the number of Nissl-stained CdlS 
in control (110.4 + 4.58) vs quinolinic acid exposed (98.3 & 10.45) striata. 
Fig. 2. Representative sections ._ __ . . ._ . _. compare posterior lateral striatal tissue after: 21 days vehicle, 2f days 
I5 mM qumolmic actd, and 21 days IS mM quinolinic acid plus four weeks recovery. Cresyl Violet 
staining was similar across the three groups. Calbindin and parvalbumin immunoreactive perikarya 
decreased after 21 days 21 mM quinolinic acid, but not different after 15 mM quinotinic acid plus four 
weeks’ recovery, when compared to vehicle. Cresyl Violet staining after 21 days vehicle (A), 21 days 
quinoiin~c acid (B), 21 days quinolinjc acid + four weeks of recovery (C). Calbindin immunoreactive 
staining 21 days vehicle (D), 21 days quinolinic acid (E), 21 days quinolinic acid + four weeks recovery 
(F). Parvalbumin immunoreactive staining 21 days vehicle (G), 21 days quinolinic acid (H) 21 days 
quinohnic acid f four weeks recovery (I). cc, Corpus cailosum. *Blood vessel provides a landmark 
for comparison of consecutive 40-ym sections from a brain exposed to 21 days quinolinic acid. 
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Scale bar = 100 urn. 
A time course evaluation of animals receiving and is sustained throughout the 21 day course of 
15 mM quinolinic acid showed that the decrease quinolinic acid delivery (Table 1). 
in calbindin and parvalbumin perikaryal immuno- The ventrolateral region of the caudal striatum 
reactivity occurs relatively rapidly (within five days), showed no change in the density of Nissl-stained cells 
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but decreased perikaryal calbindin and parvalbumin 
immunoreactivity after 21 days of 15 mM quinolinic 
acid compared to vehicle administration. If animals 
were allowed to survive either four or eight weeks 
after cessation of quinolinic acid administration, the 
number of immunoreactive calbindin and parvalbu- 
min perikarya in this brain region was not different 
from the vehicle-treated striatum (Table 1, Fig. 2). 
The number of calbindin and parvalbumin immuno- 
reactive perikarya were not different between four- 
and eight-week animals (Table 1). 
The present results show that chronic dialytic 
delivery of quinolinic acid can decrease the number of 
calbindin and parvalbumin immunoreactive peri- 
karya. The reversible nature of this effect suggests a 
change in production or distribution of these intra- 
cellular proteins. This hypothesis is further supported 
by the findings that there is no decrease in cyto- 
chrome oxidase staining or in the number of Nissl- 
stained cells in regions exhibiting transient changes in 
calcium binding proteins. 
Analysis of striata exposed to chronic dialytic 
delivery of quinolinic acid reveals three primary 
regions of specific neuronal reactions. The first re- 
gion, a central necrotic core directly adjacent to the 
probe tract, is marked by inflammatory infiltrate and 
a lack of neurons. The second region, previously 
referred to as the transition zone,4s5 is marked by an 
absence of perikaryal staining for parvalbumin and 
calbindin, a reduction in the number of Nissl-stained 
cells and a decrease in cytochrome oxidase staining. 
Though many Nissl-stained neurons in the transition 
zone appear structurally intact, a decrease in cyto- 
chrome oxidase staining suggests metabolic impair- 
ment. Beyond the transition zone is the third region, 
marked only by a decrease in perikaryal calbindin 
and parvalbumin immunoreactivity. However, unlike 
the quinolinic acid-induced decrease in cytochrome 
oxidase and Nissl cell staining in the transition 
zone, decreased calbindin and parvalbumin staining 
in the region outside the transition zone is in part 
reversible. 
There was also an increase in calbindin and parv- 
albumin neuropil staining throughout the striatum 
with both doses of quinolinic acid, and at all time 
points after 15 mM quinolinic acid delivery. This 
increase was also apparent after acute quinolinic acid 
injections,23 and may have resulted from immuno- 
histochemical neuropil staining caused by immuno- 
globulin extravasation.” 
There are at least two explanations for the transient 
decrease in perikaryal calbindin and parvalbumin 
immunoreactivity following quinolinic acid adminis- 
tration. First, it is possible that some cells were 
excluded from analysis because they were not 
distinguished from increased neuropil staining. 
However, it is unlikely that a significant number of 
cells were excluded since the increase in neuropil 
staining at no time exceeded the intensity of staining 
seen in the vast majority of perikarya from the 
homologous region of the control striatum; and 
some immunoreactive neurons could be clearly seen 
against the increased background on the lesion side 
(Figs 1, 2). 
Alternatively, the transient decrease in perikaryal 
calbindin and parvalbumin immunoreactivity may be 
caused by a change in distribution of these proteins 
within neurons. When stimulated, NMDA receptors 
allow an influx of calcium into dendritic processes 
where they are concentrated.6s22 Dendritic processes, 
which are capable of independent regulation of 
changes in intracellular calcium,8~14 could recruit 
calcium buffering proteins. Calbindin exhibits charac- 
teristics of a fast mobile calcium buffering protein, 
capable of diffusing from surrounding cytoplasm to 
local sites of calcium influx.” Ferrante and col- 
leagues’ found the intensity of calbindin immuno- 
reactivity shifts to distal dendritic arbors in HD 
striatal tissue. A similar calbindin and parvalbumin 
shift in response to quinolinic acid could explain the 
observations of decreased perikaryal staining and 
increased neuropil staining. 
It is also interesting to note that two weeks 
after acute intrastriatal quinolinic acid injection, 
levels of somatostatin and the glutamic acid decar- 
boxylase isoforms GAD65 and GAD67 were de- 
creased,16 whereas in a similar paradigm calbindin 
levels were unchanged.” It is possible that exposure 
to quinolinic acid may produce long-term effects on 
production of some cellular components, while pro- 
ducing only temporary changes in production or 
distribution of others. 
Calbindin-containing neurons appear less resist- 
ant than parvalbumin neurons to the neurodegen- 
erative effects of HD.9s’9 The present results reveal 
that chronic quinolinic acid administration also re- 
duces a greater percentage of calbindin- compared 
to parvalbumin-immunoreactive perikarya (Table 1). 
These results strengthen the contention that the pat- 
tern of neuronal vulnerability in HD is shared by stri- 
atal tissue exposed to chronic NMDA agonist 
administration. 
The importance of assessing physiological neur- 
onal states that precede cell death associated with 
neurodegenerative disorders has recently been dis- 
cussed.‘* In the present report, reversible quinolinic 
acid induced changes in calbindin and parvalbumin 
immunoreactivity may represent one such premorbid 
neuronal state. Further assessment of these changes 
may offer new insight into the neurodegenerative 
processes of HD. 
Acknowledgements-This work was supported by NSO0130, 
NS19613 and NS22157. Dr Bazzett was supported by 
training arants from The UM Reproductive Sciences 
Program -(HDO7048) and The UM Department of 
Neuroloev (NS07222-12). The authors would like to thank 
Kevin <;a&, Brady Bustany and Elizabeth Vitarbo for 
their contributions to this project. We thank one of the 










Chronic intrastriatal quinolinic acid 841 
REFERENCES 
Abercrombie R. F. and Hart C. E. (1986) Calcium and proton buffering and diffusion in isolated cytoplasm from 
Myxicola axons. Am. J. Physiol. 250, C391C405. 
Baker P. F. and Umbach J. A. (1987) Calcium buffering in axons and axoplam of Loligo. J. Physiol. 
383, 369-394. 
Bazzett T. J., Becker J. B. and Albin R. L. (1991) A novel device for chronic intracranial drug delivery via microdialysis. 
J. Neurosci. Meth. 40, l-8. 
Bazzett T. J., Becker J. B., Kaatz K. W. and Albin R. L. (1993) Chronic intrastriatal dialytic administration of 
quinolinic acid produces selective neural degeneration. Expl Neurol. 120, 177-185. 
Beal M. F., Kowall N. W., Swartz K. J., Ferrante R. J. and Martin J. B. (1989) Differential sparing of 
somatostatin-neuropeptide Y and cholinergic neurons following striatal excitotoxic lesions. Synupse 3, 3847. 
Benke T. A., Jones 0. T., Collingridge G. L. and Angelides K. J. (1993) N-Methyl-o-aspartate receptors are clustered 
and immobilized on dendrites of living cortical neurons. Proc. mtn. Acad. Sci. U.S.A. 90, 7819-7823. 
Ferrante R. J., Kowall N. W. and Richardson E. P. (1991) Proliferative and degenerative changes in striatal 
spiny neurons in Huntington’s disease: a combined study using the section-golgi method and calbindin D28k 
immunocytochemistry. J. Neurosci. 11, 3877-3887. 
Guthrie P. B., Segal M. and Kater S. B. (1991) Independent regulation of calcium revealed by imaging dendritic spines. 
Nature 354, 76-80. 
Harrington K. M. and Kowall N. W. (1991) Parvalbumin immunoreactive neurons resist degeneration in Huntington’s 
disease striatum. J. Neuropathol. exp. Neurol. 50, 309. 
10. Hartley D. M., Kurth M. C., Bjerkness L., Weiss J. H. and Choi D. W. (1993) Glutamate receptor-induced 
4sCa2+ accumulation in cortical cell culture correlates with subsequent neuronal degeneration. J. Neurosci. 
13, 1993-2000. 
11. Iacopino A., Chrisatkos S., German D., Sonsalla P. K. and Altar C. A. (1992) Calbindin-D,,,containing neurons in 
animal models of neurodegeneration: possible protection from excitotoxicity. Molec. Bruin Res. 13, 1992. 
12. Isacson 0. (1993) On neuronal health. Trends Neurosci. 16, 306-308. 
13. Kiyama H., Seto-Ohshima A. and Emson P. C. (1990) Calbindin D,,, as a marker for the degeneration of the 
striatonigral pathway in Huntington’s disease. Brain Res. 525, 209-214. 
14. Muller W. and Connor J. A. (1991) Dendritic spines as individual neuronal compartments for synaptic Ca*+ responses. 
Naiure 354, 73-76. 
15. Novelli A., Reilly J. A., Lysko P. G. and Henneberry R. C. (1988) Glutamate becomes neurotoxic via the 
N-methyl-o-aspartate receptor when intracellular energy levels are reduced. Bruin Res. 451, 205-212. 
16. Qin Y., Soghomonian J. J. and Chesselet M. F. (1992) Effects of quinolinic acid on messenger RNAs encoding 
somatostatin and glutamic acid decarboxylases in the striatum of adult rats. Expi Neurol. 115, 20&211. 
17. Roberts W. M. (1993) Spatial calcium buffering in saccular hair cells. Nature 364, 74-76. 
18. Schmidt-Kastner R., Meller D., Bellander B.-M., Stromberg I., Olson L. and Ingvar M. (1993). A one-step 
immunohistochemical method for detection of blood-brain barrier disturbances for immunoglobulins in lesioned rat 
brain with special reference to false-positive labelling in immunohistochemistry. J. Neurosci. Meth. 46, 121-132. 
19. Seto-Ohshima A., Emson P. C., Lawson E., Mountjoy C. Q. and Carrasco L. H. (1988) Loss of matrix calcium-binding 
protein-containing neurons in Huntington’s disease. Luncet 1, 1252-1255. 
20. Tsuzuki K., Iino M. and Ozawa S. (1989) Change in calcium permeability caused by quinolinic acid in cultured rat 
hippocampal neurons. Neurosci. L&f. 105, 269-274. 
21. Tymianski M., Wallace M. C., Spigelman I., Uno M., Carlen P. L., Tator C. H. and Charlton M. P. 
(1993) Cell-permeant Ca2 + chelators reduce early excitotoxic and ischemic neuronal injury in vitro and in vivo. 
Neuron 11, 221-235. 
22. Tymianski M., Charlton M. P., Carlen P. L. and Tator C. H. (1993) Source specificity of early calcium neurotoxicity 
in cultured embryonic spinal neurons. J. Neurosci. 13, 2085-2104. 
23. Waldvogel H. J., Faull R. L. M., Williams M. N. and Dragunow M. (1991) Differential sensitivity of calbindin and 
parvalbumin immunoreactive cells in the striatum to excitotoxins. Bruin Res. 546, 329-335. 
(Accepted 7 March 1994) 
